Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440179 · ClinicalTrials.gov registry record · Phase 2
SAR3419 in Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01440179 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 100 participants.
The verdict
NCT01440179, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics
Interventions
- DRUG SAR3419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01440179
The ClinicalTrials.gov registry entry for NCT01440179 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR3419 is the first listed.
NCT01440179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01440179 about?
NCT01440179 is a clinical study titled "SAR3419 in Acute Lymphoblastic Leukemia". Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics
What is the current status of trial NCT01440179?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2011-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01440179?
The interventions under investigation include: SAR3419 (DRUG).
Who is sponsoring clinical trial NCT01440179?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.